Biotechnology

Happiness Biotech Group Limited Announces Pricing of US$11 Million Firm Commitment Initial Public Offering

NANPING, China, Oct. 25, 2019 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company"), an innovativeChina-based nutraceutical and dietary supplements producer,announced today the pricing of a U.S. underwritten initial public offering ("Offering") of 2,000,000 ordinary shares at a price to...

2019-10-25 22:00 8914

Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment

PROVIDENCE, Rhode Island, Oct. 23, 2019 /PRNewswire/ -- Announced today, Chugai Pharmaceutical Co., Ltd. ("Chugai"), a member of the Roche Group, will extend the company's licensed access to theImmunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc. ...

2019-10-23 04:10 1679

TissueCypher® Further Validated to Accurately Risk Stratify Barrett's Esophagus Patients With Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences

Data presented at ACG, UEGW illustrates the fourth independent validation of TissueCypher performance for risk stratifying non-dysplasticBarrett's esophagus (NDBE) patients; expands indication for testing low-grade dysplasia (LGD) PITTSBURGH, Oct. 23, 2019 /PRNewswire/ -- Cernostics, developer of...

2019-10-23 01:59 1298

New Horizon Health and Prenetics Establish Strategic Partnership to Launch ColoClear, the Chinese rival to ColoGuard, in Hong Kong and Southeast Asia

* ColoGuard, owned by Exact Sciences is one of the most successful genomics companies in the World, currently listed on the Nasdaq with a market cap ofUSD 12 Billion. * ColoClear will be the region's 1st non-invasive DNA stool test to screen for colorectal cancer at 92%,which can be done in t...

2019-10-21 20:00 1578

Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma

SUZHOU, China, Oct. 21, 2019 /PRNewswire/ --  Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today ...

2019-10-21 08:00 2387

China Biologic Special Committee Retains Financial Advisor and Legal Counsel

BEIJING, Oct. 17, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the special committee (the "Special Committee") of the Company's board o...

2019-10-17 20:00 11302

GELITA & Geltor Sign Letter of Intent to Commercialize First Animal-Free Biodesigned Collagen for Dietary Supplements, a Market with Huge Growth Potential

LAS VEGAS, Oct. 17, 2019 /PRNewswire/ -- In the halls of the SupplySide West (SSW) Expo, officials from both GELITA and Geltor signed a letter of intent for developing, producing and marketing the first ingestible animal-free collagen proteins – to be launched in late 2020. In this arrangement, G...

2019-10-17 18:32 1661

MetGen Earns Acclaim from Frost & Sullivan for its Unique, Customized Enzyme Technologies, METNIN™ and ENZINE®

The technologies solve the industry's major pain points regarding the valorization of lignin, shorter technology development cycles, and customization of enzymes for different applications LONDON, Oct. 17, 2019 /PRNewswire/ -- Based on its recent analysis of the European industrial enzymes marke...

2019-10-17 15:00 1014

Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer

Interim CEO unanimously chosen to lead global operations in patient-first oncology innovation WOBURN, Mass., Oct. 16, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced the appointment ofKevin R. Smith as Chief Executive Officer of Sir...

2019-10-16 22:00 1869

The 26th China Yangling Agricultural High-tech Achievements Expo will begin on October 22

YANGLING, China, Oct. 16, 2019 /PRNewswire/ -- On October 15, over ten international reporters, representing, among others, the European Pressphoto Agency, the Colpisa News Agency, the Korean Central News Agency, Radio-Television Slovenia, and the Republic of Korea's "Asian Economy", visited Yan...

2019-10-16 19:28 1319

Curiox Biosystems Achieves Commercialisation and Fund Raising Success in North Asia with the Support of Cornerstone Investor, ZIG Ventures

* CURIOX BIOSYSTEMS, is an A*STAR spinoff company, that develops bioinstrumentation solutions used in cell analysis and therapy for the pharmaceutical and biotech industries. The company has successfully penetrated theUSA, PRC, Korean and European markets and also secured a Series B funding of ...

2019-10-16 07:00 1836

Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution

SEOUL, South Korea, and RIJSWIJK, The Netherlands, Oct. 15, 2019 /PRNewswire/ -- Celemics, provider of NGS target enrichment kits and innovative sequencing platforms, announced today the release of a comprehensive NGS target enrichment workflow for clinical and translational research applications...

2019-10-15 19:00 1775

WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules

SHANGHAI and CAMBRIDGE, Massachusetts and SANKT AUGUSTIN, Germany, Oct. 10, 2019 /PRNewswire/ -- WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's library of novel drug-like scaffolds, GalaXi® offers a...

2019-10-11 08:02 7876

CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million

HONG KONG and NANJING, China, Oct. 9, 2019 /PRNewswire/ -- Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceu...

2019-10-09 20:58 2040

Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ -- - RESILIENT Protocol captures Encyclopedic information from tumors and uses Artificial Intelligence (AI) to optimize treatments; - Objective Response and Disease Control Comparable to or better than most Immunotherapy opti...

2019-10-09 17:56 1409

Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer

HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Han...

2019-10-08 08:00 2663

Cross-industrial technologies make a splash in Asia Agri-Tech Expo in Taipei

TAIPEI, Oct. 5, 2019 /PRNewswire/ -- The Asia Agri-Tech Expo & Forum 2019 will take place at Taipei Nangang Exhibition Center Hall 1 fromOctober 31 to November 2. Organised by Informa Markets of Taiwan Office (UBM Taiwan), the tradeshow features innovative, eco-friendly and sustainable manufac...

2019-10-05 10:06 3547

Medicago's New Drug Submission accepted for scientific review by Health Canada: An important step for Medicago towards commercialization of its innovative influenza vaccine

QUEBEC CITY, Oct. 3, 2019 /PRNewswire/ -- Medicago, a biotechnology company and global leader in the development and production of plant-derived vaccines with headquarters inQuebec City, announces today that Health Canada accepted for scientific review its New Drug Submission (NDS) for a plant-ba...

2019-10-03 06:30 1505

AGC Biologics Appoints New Site Head/General Manager of Copenhagen, Denmark Operations

Jeffrey D. Mowery Named Site Head/General Manager BOTHELL, Washington, Oct. 1, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment ofJeffery D. Mowery as Site Head/General Manager of theCopenhagen,...

2019-10-01 07:00 2311

Interleukin 11 Identified as New Therapeutic Target for Idiopathic Pulmonary Fibrosis

* Idiopathic pulmonary fibrosis (IPF) is a severe and fatal disease that causes lung damage and scarring * Blocking a protein called interleukin-11 (IL11), which is abnormally high in the lungs of patients with IPF, can reverse lung fibrosis and scarring in preclinical studies * Enleofen Bi...

2019-09-30 15:00 1072
1 ... 295296297298299